Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Vincenzo Altieri
Phase II Trial of Cisplatin Plus Prednisone in Docetaxel-Refractory Castration-Resistant Prostate Cancer Patients
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Related publications
Phase II Randomized Study of Figitumumab Plus Docetaxel and Docetaxel Alone With Crossover for Metastatic Castration-Resistant Prostate Cancer
Clinical Cancer Research
Cancer Research
Oncology
Salvage Therapy for Castration-Refractory Prostate Cancer Resistant to Docetaxel
Japanese Journal of Urology
Urology
Phase II, Multicenter, Randomized Trial of Docetaxel Plus Prednisone With or Without Cediranib in Men With Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer
Oncologist
Cancer Research
Medicine
Oncology
Phase II Pilot Study of the Prednisone to Dexamethasone Switch in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients With Limited Progression on Abiraterone Plus Prednisone (SWITCH Study)
British Journal of Cancer
Cancer Research
Oncology
Phase I Trial With a Combination of Docetaxel and 153Sm-Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer
Urologic Oncology: Seminars and Original Investigations
Oncology
Urology
Docetaxel Rechallenge in Patients With Castration-Resistant Prostate Cancer — A Review
European Oncology and Haematology
Oncology
Hematology
A Phase II Trial of Prostate-Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) in Taxane-Refractory Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) With Docetaxel in Metastatic Castration‐Resistant Prostate Cancer (mCRPC)
Oncologist
Cancer Research
Medicine
Oncology
Guideline Adherence in Docetaxel Treatment of Castration Resistant Prostate Cancer (CRPC) Patients in a Real-World Population: The Castration Resistant Prostate Cancer Registry (CAPRI) in the Netherlands
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
